Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Recent share performance and business snapshot

Solvay (ENXTBR:SOLB) has been on many investors' screens after the stock declined around 4% over the past month and about 6% over the past 3 months, prompting closer attention to its current valuation.

The company, headquartered in Brussels, focuses on basic and performance chemicals used in sectors such as glass, electric vehicle batteries, detergents, healthcare and semiconductors, with revenue of €4,645.0 million and a reported loss of €25.0 million.

See our latest analysis for Solvay.

At the current share price of €26.22, Solvay's recent 1 month and year to date share price returns of around 6% and 4% declines show fading momentum, even though the 3 year total shareholder return of about 44% points to a stronger longer term outcome.

If you are weighing Solvay's recent pullback and want to broaden your options, this could be a good moment to scan 30 best rare earth metal stocks

With Solvay trading at €26.22, sitting on a reported loss and an estimated intrinsic discount of about 39%, the real question is whether this signals an undervalued chemicals stock or if the market already reflects its future growth potential.

Most Popular Narrative: 4% Overvalued

Solvay's most followed narrative sets a fair value around €25.34, slightly below the current €26.22 share price, and hinges on specific earnings and margin assumptions.

Growing customer demand for rare earth production capacity outside of China, triggered by Chinese export controls and seeking greater supply chain localization, positions Solvay's La Rochelle plant for potential rapid expansion, paving the way for incremental high-value revenue streams and improved asset utilization in the coming years.

Read the complete narrative.

Want to see what sits behind that rare earths story and the fair value maths? The narrative leans on revenue mix shifts, margin rebuild, and future earnings power assumptions.

Result: Fair Value of €25.34 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this narrative could be knocked off course if pricing pressure in soda ash persists, or if environmental remediation costs eat further into cash flow and flexibility.

Find out about the key risks to this Solvay narrative.

Another View Using Market Ratios

While the narrative and analyst targets suggest Solvay is around 4% overvalued, the current P/S ratio of 0.6x tells a different story. That level sits below the European chemicals industry average of 1.1x and in line with both peers and the 0.6x fair ratio, which points to relatively limited valuation stretch. This raises an important question: is the tension between earnings expectations and sales-based pricing hinting at risk, or at a potential opportunity if sentiment turns?